The 7 most recent market catalysts affecting $MANE, each scored for sentiment and estimated stock impact. Sourced from SEC EDGAR filings and financial news, analysed automatically as they are published.
Aug 11, 2026
Corporate Catalyst
Bullish
Impact 85
Veradermics Q2 EPS $(0.58) Beats $(0.65) Estimate
Veradermics announced its Q2 earnings, reporting a loss of $(0.58) per share. This figure not only beat the consensus analyst estimate of $(0.65) but also marked a dramatic 97.6% i…
Jul 17, 2026
Corporate Catalyst
Neutral
Impact 75
Veradermics Presents Data From Phase 2/3 Trial 302 Of VDPHL01 In Male Participants With Mid-To-Moderate Pattern Hair Loss
Veradermics (MANE) is presenting subgroup analysis data from its Phase 2/3 clinical trial for VDPHL01, a treatment for male pattern hair loss. The announcement of data presentation…
Jul 16, 2026
Corporate Catalyst
Bullish
Impact 65
Citigroup Maintains Buy on Veradermics, Raises Price Target to $160
Citigroup analyst Geoff Meacham has maintained a 'Buy' rating on Veradermics (NYSE: MANE) and raised the price target from $135 to $160. This action signals a strong vote of confid…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 75
Veradermics' Oral Hair Loss Drug for Women Shows Results In Just 2 Months
Veradermics (MANE) released positive topline results from its open-label Phase 2 trial for VDPHL01, an oral drug targeting female pattern hair loss. The study demonstrated clinical…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 55
Needham Maintains Buy on Veradermics, Raises Price Target to $164
Needham analyst Serge Belanger maintained a 'Buy' rating on Veradermics (MANE) and raised the price target from $136 to $164. This action indicates increased confidence from a prom…
Jul 15, 2026
Corporate Catalyst
Bullish
Impact 85
Veradermics’ VDPHL01 Phase 2 Trial Met Key Endpoints In Female Pattern Hair Loss, Showing Rapid Onset Of Hair Growth, 88.9%–90.0% Patient‑Reported Improvement At Month 6; Topline Phase 2/3 Study 306 Results Expected In H1 2027
Veradermics (MANE) announced highly positive topline results from its Phase 2 clinical trial (Study '207') for VDPHL01, an oral minoxidil formulation for female pattern hair loss. …
Jul 15, 2026
Corporate Catalyst
Neutral
Impact 65
B. Riley Securities Initiates Coverage On Veradermics with Buy Rating, Announces Price Target of $170
B. Riley Securities analyst Mayank Mamtani has initiated coverage on Veradermics (MANE) with a 'Buy' rating and a $170 price target. This event is significant as new analyst covera…
Not financial advice. AI-generated analysis for informational purposes only. Tradow AI LLC is not a registered investment adviser.